Medivation (NASDAQ:MDVN) dropped by -0.75 or -0.45 points during the last session to $59.03 per share. One of the highlights of the day was the net money flow figure, which stood at $1.66 million even as the stock accepted $14.29 million in upticks but rejected $12.63 million in downticks. The up/down ratio for the last observation was a 1.13. The 1-week percentage change for the stock price is registered at -0.51%.A block transaction occurred with $1.76 million in upticks and $0.68 million in downticks while the up/down ratio was calculated to be 2.58. The stock witnessed a net inflow of $1.08 million at the end of the block trade.
The stock has recorded a 20-day Moving Average of 2.18% and the 50-Day Moving Average is 2.19%. The company shares have rallied 2.48% in the past 52 Weeks. On May 10, 2016 The shares registered one year high of $62.94 and one year low was seen on February 9, 2016 at $26.41. The 50-day moving average is $60.34 and the 200 day moving average is recorded at $45.72. S&P 500 has rallied 1.93% during the last 52-weeks.
Medivation (NASDAQ:MDVN): The stock opened at $59.35 on Tuesday but the bulls could not build on the opening and the stock topped out at $59.83 for the day. The stock traded down to $58.61 during the day, due to lack of any buying support eventually closed down at $58.97 with a loss of -0.84% for the day. The stock had closed at $59.47 on the previous day. The total traded volume was 2,215,293 shares.
Currently the company Insiders own 4% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.41% . Institutional Investors own 90.82% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of 0.7%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., had unloaded 2,578 shares at an average price of $60.42 in a transaction dated on June 6, 2016. The total value of the transaction was worth $155,763.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.